6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The mitochondrial fission protein, Dynamin related protein 1 (Drp1), and its upstream protein calcium/calmodulin–dependent protein kinase I (CaMKI) play a critical role in chemoresistance in ovarian cancer (OVCA). Thus, we examined the expression of Drp1, CaMKI and their phosphorylated forms and their prognostic impact in epithelial OVCA patients.

          Methods

          Expression analysis was performed by immunohistochemistry (IHC) of paraffin-embedded tumor samples from 49 patients with epithelial OVCA. Staining intensity and the percentage of positively stained tumor cells were used to calculate an immunoreactive score (IRS) of 0–12. The expression scores calculated were correlated with clinicopathological parameters and patient survival.

          Results

          High immunoreactivity of phospho-Drp1 Ser637 was significantly correlated with high-grade serous carcinoma (HGSC) ( p = 0.034), residual postoperative tumor of > 1 cm ( p = 0.006), and non-responders to adjuvant chemotherapy ( p = 0.007), whereas high expression of CaMKI was significantly correlated with stage III/IV [International Federation of Gynecologists and Obstetricians (FIGO)] ( p = 0.011) and platinum-resistant recurrence ( p = 0.030). ROC curve analysis showed that Drp1, phospho-Drp1 Ser637 and CaMKI could significantly detect tumor progression with 0.710, 0.779, and 0.686 of area under the curve (AUC), respectively. The Kaplan-Meier survival curve showed that patients with high Drp1, phospho-Drp1 Ser637 and CaMKI levels had significantly poorer progression free survival (PFS) ( p = 0.003, p < 0.001 and p = 0.017, respectively). Using multivariate analyses, phospho-Drp1 Ser637 was significantly associated with PFS [ p = 0.043, hazard ratio (HR) 3.151, 95% confidence interval (CI) 1.039–9.561].

          Conclusions

          Drp1 and CaMKI are novel potential candidates for the detection and prognosis of epithelial OVCA and as such further studies should be performed to exploit their therapeutic significance.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: not found
          • Article: not found

          Mitochondrial dynamics--mitochondrial fission and fusion in human diseases.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Chemotherapy Resistance in Advanced Ovarian Cancer Patients

            Ovarian cancer is the seventh most common gynaecologic malignancy seen in women. Majority of the patients with ovarian cancer are diagnosed at the advanced stage making prognosis poor. The standard management of advanced ovarian cancer includes tumour debulking surgery followed by chemotherapy. Various types of chemotherapeutic regimens have been used to treat advanced ovarian cancer, but the most promising and the currently used standard first-line treatment is carboplatin and paclitaxel. Despite improved clinical response and survival to this combination of chemotherapy, numerous patients either undergo relapse or succumb to the disease as a result of chemotherapy resistance. To understand this phenomenon at a cellular level, various macromolecules such as DNA, messenger RNA and proteins have been developed as biomarkers for chemotherapy response. This review comprehensively summarizes the problem that pertains to chemotherapy resistance in advanced ovarian cancer and provides a good overview of the various biomarkers that have been developed in this field.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells

                Bookmark

                Author and article information

                Contributors
                go242h@yahoo.co.jp
                Journal
                BMC Cancer
                BMC Cancer
                BMC Cancer
                BioMed Central (London )
                1471-2407
                24 May 2020
                24 May 2020
                2020
                : 20
                : 467
                Affiliations
                [1 ]GRID grid.163577.1, ISNI 0000 0001 0692 8246, Department of Obstetrics and Gynecology, , University of Fukui, ; 23-3 Matsuoka-Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193 Japan
                [2 ]GRID grid.28046.38, ISNI 0000 0001 2182 2255, Departments of Obstetrics & Gynecology and Cellular & Molecular Medicine, and Interdisciplinary School of Health Sciences, , University of Ottawa, ; Ottawa, ON K1H 8L1 Canada
                [3 ]GRID grid.412687.e, ISNI 0000 0000 9606 5108, Chronic Disease Program, Ottawa Hospital Research Institute, ; Ottawa, ON K1H 8L6 Canada
                Author information
                http://orcid.org/0000-0001-5765-5460
                Article
                6965
                10.1186/s12885-020-06965-4
                7247242
                32448194
                77e7d6c4-c167-4871-869c-8048e74ac2cb
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 8 February 2020
                : 14 May 2020
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100011746, NOVARTIS Foundation (Japan) for the Promotion of Science;
                Award ID: B-17K16840
                Award Recipient :
                Funded by: Canadian Institute of Health Research
                Award ID: MOP-15691
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2020

                Oncology & Radiotherapy
                epithelial ovarian cancer,drp1,phospho-drp1ser637,camki,prognostic biomarker

                Comments

                Comment on this article